{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:01:36Z","timestamp":1793908896008,"version":"4.8.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Inherited cardiomyopathies are common cardiac diseases worldwide, leading in the late stage to heart failure and death. The most promising treatments against these diseases are small molecules directly modulating the force produced by \u03b2-cardiac myosin, the molecular motor driving heart contraction. Omecamtiv mecarbil and Mavacamten are two such molecules that completed phase 3 clinical trials, and the inhibitor Mavacamten is now approved by the FDA. In contrast to Mavacamten, Omecamtiv mecarbil acts as an activator of cardiac contractility. Here, we reveal by X-ray crystallography that both drugs target the same pocket and stabilize a pre-stroke structural state, with only few local differences. All-atom molecular dynamics simulations reveal how these molecules produce distinct effects in motor allostery thus impacting force production in opposite way. Altogether, our results provide the framework for rational drug development for the purpose of personalized medicine.<\/jats:p>","DOI":"10.1038\/s41467-024-47587-9","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T17:01:44Z","timestamp":1717779704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-9096","authenticated-orcid":false,"given":"Daniel","family":"Auguin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6102-2025","authenticated-orcid":false,"given":"Julien","family":"Robert-Paganin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2089-6727","authenticated-orcid":false,"given":"St\u00e9phane","family":"R\u00e9ty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5928-2776","authenticated-orcid":false,"given":"Carlos","family":"Kikuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Theumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt W.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9631-5239","authenticated-orcid":false,"given":"Hans-Joachim","family":"Kn\u00f6lker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-0336","authenticated-orcid":false,"given":"Anne","family":"Houdusse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"47587_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-genom-083118-015306","volume":"20","author":"R Yotti","year":"2019","unstructured":"Yotti, R., Seidman, C. E. & Seidman, J. G. Advances in the genetic basis and pathogenesis of sarcomere cardiomyopathies. Annu. Rev. Genomics Hum. Genet. 20, 129\u2013153 (2019).","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"47587_CR2","doi-asserted-by":"publisher","first-page":"17831","DOI":"10.1073\/pnas.1910962116","volume":"116","author":"SR Clippinger","year":"2019","unstructured":"Clippinger, S. R. et al. Disrupted mechanobiology links the molecular and cellular phenotypes in familial dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA 116, 17831\u201317840 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"47587_CR3","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.bpj.2014.02.011","volume":"106","author":"JA Spudich","year":"2014","unstructured":"Spudich, J. A. Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. Biophys. J. 106, 1236\u20131249 (2014).","journal-title":"Biophys. J."},{"key":"47587_CR4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1161\/CIRCHEARTFAILURE.114.001843","volume":"8","author":"D Pasqualucci","year":"2015","unstructured":"Pasqualucci, D. et al. Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy. Circ. Heart Fail. 8, 1014\u20131021 (2015).","journal-title":"Circ. Heart Fail."},{"key":"47587_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","volume":"6","author":"BJ Maron","year":"2018","unstructured":"Maron, B. J., Rowin, E. J., Udelson, J. E. & Maron, M. S. Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy. JACC Heart Fail. 6, 353\u2013363 (2018).","journal-title":"JACC Heart Fail."},{"key":"47587_CR6","first-page":"1","volume":"3","author":"A Albakri","year":"2019","unstructured":"Albakri, A. Inherited cardiomyopathies: a review and pooled analysis of pathophysiology, diagnosis and clinical management. Intern. Med. Care 3, 1\u201318 (2019).","journal-title":"Intern. Med. Care"},{"key":"47587_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/CIRCRESAHA.116.309396","volume":"121","author":"EM McNally","year":"2017","unstructured":"McNally, E. M. & Mestroni, L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ. Res. 121, 731\u2013748 (2017).","journal-title":"Circ. Res."},{"key":"47587_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1172\/JCI62862","volume":"123","author":"EM McNally","year":"2013","unstructured":"McNally, E. M., Golbus, J. R. & Puckelwartz, M. J. Genetic mutations and mechanisms in dilated cardiomyopathy. J. Clin. Invest. 123, 19\u201326 (2013).","journal-title":"J. Clin. Invest."},{"key":"47587_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jjcc.2014.02.022","volume":"64","author":"M Hamada","year":"2014","unstructured":"Hamada, M., Ikeda, S. & Shigematsu, Y. Advances in medical treatment of hypertrophic cardiomyopathy. J. Cardiol. 64, 1\u201310 (2014).","journal-title":"J. Cardiol."},{"key":"47587_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/acs.chemrev.9b00264","volume":"120","author":"J Robert-Paganin","year":"2020","unstructured":"Robert-Paganin, J., Pylypenko, O., Kikuti, C., Sweeney, H. L. & Houdusse, A. Force generation by myosin motors: a structural perspective. Chem. Rev. 120, 5\u201335 (2020).","journal-title":"Chem. Rev."},{"key":"47587_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38698-w","volume":"14","author":"A Grinzato","year":"2023","unstructured":"Grinzato, A. et al. Cryo-EM structure of the folded-back state of human \u03b2-cardiac myosin. Nat. Commun. 14, 3166 (2023).","journal-title":"Nat. Commun."},{"key":"47587_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/s41586-023-06690-5","volume":"623","author":"D Tamborrini","year":"2023","unstructured":"Tamborrini, D. et al. Structure of the native myosin filament in the relaxed cardiac sarcomere. Nature 623, 863\u2013871 (2023).","journal-title":"Nature"},{"key":"47587_CR13","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s41586-023-06691-4","volume":"623","author":"D Dutta","year":"2023","unstructured":"Dutta, D., Nguyen, V., Campbell, K. S., Padr\u00f3n, R. & Craig, R. Cryo-EM structure of the human cardiac myosin filament. Nature 623, 853\u2013862 (2023).","journal-title":"Nature"},{"key":"47587_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00424-019-02259-2","volume":"471","author":"JA Spudich","year":"2019","unstructured":"Spudich, J. A. Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. Pflugers Arch. 471, 701\u2013717 (2019).","journal-title":"Pflugers Arch."},{"key":"47587_CR15","doi-asserted-by":"crossref","unstructured":"Trivedi, D. V., Nag, S., Spudich, A., Ruppel, K. M. & Spudich, J. A. The myosin family of mechanoenzymes: from mechanisms to therapeutic approaches. Annu. Rev. Biochem. 89, 667\u2013693 (2020).","DOI":"10.1146\/annurev-biochem-011520-105234"},{"key":"47587_CR16","doi-asserted-by":"publisher","first-page":"e148557","DOI":"10.1172\/JCI148557","volume":"132","author":"SM Day","year":"2022","unstructured":"Day, S. M., Tardiff, J. C. & Ostap, E. M. Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure. J. Clin. Invest. 132, e148557 (2022).","journal-title":"J. Clin. Invest."},{"key":"47587_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink, J. R. et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N. Engl. J. Med. 384, 105\u2013116 (2021).","journal-title":"N. Engl. J. Med."},{"key":"47587_CR18","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green, E. M. et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351, 617\u2013621 (2016).","journal-title":"Science"},{"key":"47587_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40256-023-00599-0","volume":"23","author":"SA Sebastian","year":"2023","unstructured":"Sebastian, S. A., Padda, I., Lehr, E. J. & Johal, G. Aficamten: a breakthrough therapy for symptomatic obstructive hypertrophic cardiomyopathy. Am. J. Cardiovasc. drugs 23, 519\u2013532 (2023).","journal-title":"Am. J. Cardiovasc. drugs"},{"key":"47587_CR20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1161\/CIRCHEARTFAILURE.109.930321","volume":"3","author":"S You-Tang","year":"2010","unstructured":"You-Tang, S. et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ. Heart Fail. 3, 522\u2013527 (2010).","journal-title":"Circ. Heart Fail."},{"key":"47587_CR21","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1126\/science.1200113","volume":"331","author":"FI Malik","year":"2011","unstructured":"Malik, F. I. et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 331, 1439\u20131443 (2011).","journal-title":"Science"},{"key":"47587_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1113\/JP275050","volume":"596","author":"T Kampourakis","year":"2018","unstructured":"Kampourakis, T., Zhang, X., Sun, Y.-B. & Irving, M. Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament. J. Physiol. 596, 31\u201346 (2018).","journal-title":"J. Physiol."},{"key":"47587_CR23","doi-asserted-by":"crossref","unstructured":"Anderson, R. L. et al. Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc. Natl. Acad. Sci. USA. 115, E8143\u2013E8152 (2018).","DOI":"10.1073\/pnas.1809540115"},{"key":"47587_CR24","doi-asserted-by":"crossref","unstructured":"Rohde, J. A., Roopnarine, O., Thomas, D. D. & Muretta, J. M. Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin. Proc. Natl. Acad. Sci. USA. 115 E7486\u2013E7494 (2018).","DOI":"10.1073\/pnas.1720342115"},{"key":"47587_CR25","doi-asserted-by":"publisher","first-page":"101157","DOI":"10.1016\/j.jbc.2021.101157","volume":"297","author":"S Chu","year":"2021","unstructured":"Chu, S., Muretta, J. M. & Thomas, D. D. Direct detection of the myosin super-relaxed state and interacting-heads motif in solution. J. Biol. Chem. 297, 101157 (2021).","journal-title":"J. Biol. Chem."},{"key":"47587_CR26","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1074\/jbc.M116.748780","volume":"292","author":"AM Swenson","year":"2017","unstructured":"Swenson, A. M. et al. Omecamtiv mecarbil enhances the duty ratio of human \u03b2-Cardiac myosin resulting in increased calcium sensitivity and slowed force development in cardiac muscle. J. Biol. Chem. 292, 3768\u20133778 (2017).","journal-title":"J. Biol. Chem."},{"key":"47587_CR27","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1021\/bi5015166","volume":"54","author":"Y Liu","year":"2015","unstructured":"Liu, Y., White, H. D., Belknap, B., Winkelmann, D. A. & Forgacs, E. Omecamtiv mecarbil modulates the kinetic and motile properties of porcine \u03b2-Cardiac myosin. Biochemistry 54, 1963\u20131975 (2015).","journal-title":"Biochemistry"},{"key":"47587_CR28","doi-asserted-by":"publisher","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","volume":"292","author":"RF Kawas","year":"2017","unstructured":"Kawas, R. F. et al. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J. Biol. Chem. 292, 16571\u201316577 (2017).","journal-title":"J. Biol. Chem."},{"key":"47587_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00176-5","volume":"8","author":"VJ Planelles-Herrero","year":"2017","unstructured":"Planelles-Herrero, V. J., Hartman, J. J., Robert-Paganin, J., Malik, F. I. & Houdusse, A. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat. Commun. 8, 190 (2017).","journal-title":"Nat. Commun."},{"key":"47587_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06193-2","volume":"9","author":"MS Woody","year":"2018","unstructured":"Woody, M. S. et al. Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke. Nat. Commun. 9, 3838 (2018).","journal-title":"Nat. Commun."},{"key":"47587_CR31","doi-asserted-by":"publisher","first-page":"e63691","DOI":"10.7554\/eLife.63691","volume":"10","author":"A Snoberger","year":"2021","unstructured":"Snoberger, A. et al. Myosin with hypertrophic cardiac mutation R712L has a decreased working stroke which is rescued by omecamtiv mecarbil. Elife 10, e63691 (2021).","journal-title":"Elife"},{"key":"47587_CR32","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.7554\/eLife.24634","volume":"6","author":"L Alamo","year":"2017","unstructured":"Alamo, L. et al. Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes. Elife 6, 2386\u20132390 (2017).","journal-title":"Elife"},{"key":"47587_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nsmb.3408","volume":"24","author":"S Nag","year":"2017","unstructured":"Nag, S. et al. The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. Nat. Struct. Mol. Biol. 24, 525\u2013533 (2017).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"47587_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06191-4","volume":"9","author":"J Robert-Paganin","year":"2018","unstructured":"Robert-Paganin, J., Auguin, D. & Houdusse, A. Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition. Nat. Commun. 9, 4019 (2018).","journal-title":"Nat. Commun."},{"key":"47587_CR35","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.76805","volume":"11","author":"MM Morck","year":"2022","unstructured":"Morck, M. M. et al. Hypertrophic cardiomyopathy mutations in the pliant and light chain-binding regions of the lever arm of human \u03b2-cardiac myosin have divergent effects on myosin function. Elife 11, e76805 (2022).","journal-title":"Elife"},{"key":"47587_CR36","doi-asserted-by":"publisher","first-page":"17314","DOI":"10.1074\/jbc.RA119.010217","volume":"294","author":"W Tang","year":"2019","unstructured":"Tang, W., Unrath, W. C., Desetty, R. & Yengo, C. M. Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil. J. Biol. Chem. 294, 17314\u201317325 (2019).","journal-title":"J. Biol. Chem."},{"key":"47587_CR37","unstructured":"Tickle, I. J. et al. (2016). STARANISO (Global Phasing Ltd., 2016)."},{"key":"47587_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11120-0","volume":"10","author":"J Robert-Paganin","year":"2019","unstructured":"Robert-Paganin, J. et al. Plasmodium myosin A drives parasite invasion by an atypical force generating mechanism. Nat. Commun. 10, 3286 (2019).","journal-title":"Nat. Commun."},{"key":"47587_CR39","doi-asserted-by":"publisher","first-page":"e60581","DOI":"10.7554\/eLife.60581","volume":"9","author":"D Moussaoui","year":"2020","unstructured":"Moussaoui, D. et al. Full-length Plasmodium falciparum myosin A and essential light chain PfELC structures provide new anti-malarial targets. Elife 9, e60581 (2020).","journal-title":"Elife"},{"key":"47587_CR40","doi-asserted-by":"publisher","first-page":"e1005826","DOI":"10.1371\/journal.pcbi.1005826","volume":"13","author":"S Hashem","year":"2017","unstructured":"Hashem, S., Tiberti, M. & Fornili, A. Allosteric modulation of cardiac myosin dynamics by omecamtiv mecarbil. PLoS Comput. Biol. 13, e1005826 (2017).","journal-title":"PLoS Comput. Biol."},{"key":"47587_CR41","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1021\/acs.jcim.0c00953","volume":"60","author":"S Hashem","year":"2020","unstructured":"Hashem, S., Davies, W. G. & Fornili, A. Heart failure drug modifies the intrinsic dynamics of the pre-power stroke state of cardiac myosin. J. Chem. Inf. Model. 60, 6438\u20136446 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"47587_CR42","doi-asserted-by":"publisher","first-page":"10069","DOI":"10.1021\/acs.jpcb.2c06679","volume":"126","author":"A Chakraborti","year":"2022","unstructured":"Chakraborti, A., Tardiff, J. C. & Schwartz, S. D. Insights into the mechanism of the cardiac drug Omecamtiv Mecarbil\u2500A computational study. J. Phys. Chem. B 126, 10069\u201310082 (2022).","journal-title":"J. Phys. Chem. B"},{"key":"47587_CR43","doi-asserted-by":"publisher","first-page":"e1011099","DOI":"10.1371\/journal.pcbi.1011099","volume":"19","author":"F Akter","year":"2023","unstructured":"Akter, F., Ochala, J. & Fornili, A. Binding pocket dynamics along the recovery stroke of human \u03b2-cardiac myosin. PLoS Comput. Biol. 19, e1011099 (2023).","journal-title":"PLoS Comput. Biol."},{"key":"47587_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.devcel.2015.03.025","volume":"33","author":"P Llinas","year":"2015","unstructured":"Llinas, P. et al. How actin initiates the motor activity of myosin. Dev. Cell 33, 401\u2013412 (2015).","journal-title":"Dev. Cell"},{"key":"47587_CR45","doi-asserted-by":"publisher","first-page":"9599","DOI":"10.3390\/ijms21249599","volume":"21","author":"K Alsulami","year":"2020","unstructured":"Alsulami, K. & Marston, S. Small molecules acting on myofilaments as treatments for heart and skeletal muscle diseases. Int. J. Mol. Sci. 21, 9599 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"47587_CR46","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40265-022-01739-7","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam, S. J. Mavacamten: first approval. Drugs 82, 1127\u20131135 (2022).","journal-title":"Drugs"},{"key":"47587_CR47","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.cell.2020.08.050","volume":"183","author":"M Gyimesi","year":"2020","unstructured":"Gyimesi, M. et al. Single residue variation in skeletal muscle myosin enables direct and selective drug targeting for spasticity and muscle stiffness. Cell 183, 335\u2013346 (2020).","journal-title":"Cell"},{"key":"47587_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38976-7","volume":"14","author":"D Moussaoui","year":"2023","unstructured":"Moussaoui, D. et al. Mechanism of small molecule inhibition of Plasmodium falciparum myosin A informs antimalarial drug design. Nat. Commun. 14, 3463 (2023).","journal-title":"Nat. Commun."},{"key":"47587_CR49","doi-asserted-by":"publisher","first-page":"E7448","DOI":"10.1073\/pnas.1609342113","volume":"113","author":"S Sirigu","year":"2016","unstructured":"Sirigu, S. et al. Highly selective inhibition of myosin motors provides the basis of potential therapeutic application. Proc. Natl. Acad. Sci. USA 113, E7448\u2013E7455 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"47587_CR50","unstructured":"Oslob, J. et al. Pyrimidinedione compounds against cardiac conditions. WIPO-PCT, International Patent, WO 2014\/205223 A1 (2014)."},{"key":"47587_CR51","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"47587_CR52","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1107\/S0907444911007773","volume":"67","author":"C Vonrhein","year":"2011","unstructured":"Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D Biol. Crystallogr. 67, 293\u2013302 (2011).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"47587_CR53","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"47587_CR54","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"47587_CR55","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"47587_CR56","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. Sect. D Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr. Sect. D Struct. Biol."},{"key":"47587_CR57","unstructured":"Bricogne G. et al. BUSTER version X.Y.Z. (Global Phasing Ltd., 2017)."},{"key":"47587_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1\u20132","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1\u20132, 19\u201325 (2015).","journal-title":"SoftwareX"},{"key":"47587_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nmeth.4067","volume":"14","author":"J Huang","year":"2017","unstructured":"Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat. Methods 14, 71\u201373 (2017).","journal-title":"Nat. Methods"},{"key":"47587_CR60","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcc.21287","volume":"30","author":"BR Brooks","year":"2009","unstructured":"Brooks, B. R. et al. CHARMM: The biomolecular simulation program. J. Comput. Chem. 30, 1545\u20131614 (2009).","journal-title":"J. Comput. Chem."},{"key":"47587_CR61","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jcc.20945","volume":"29","author":"S Jo","year":"2008","unstructured":"Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 29, 1859\u20131865 (2008).","journal-title":"J. Comput. Chem."},{"key":"47587_CR62","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1021\/jp973084f","volume":"102","author":"AD MacKerell","year":"1998","unstructured":"MacKerell, A. D. et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102, 3586\u20133616 (1998).","journal-title":"J. Phys. Chem. B"},{"key":"47587_CR63","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1063\/1.470117","volume":"103","author":"U Essmann","year":"1995","unstructured":"Essmann, U. et al. A smooth particle mesh Ewald method. J. Chem. Phys. 103, 8577\u20138593 (1995).","journal-title":"J. Chem. Phys."},{"key":"47587_CR64","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1021\/ct9001015","volume":"5","author":"DS Cerutti","year":"2009","unstructured":"Cerutti, D. S., Duke, R. E., Darden, T. A. & Lybrand, T. P. Staggered mesh Ewald: an extension of the smooth particle-mesh Ewald method adding great versatility. J. Chem. Theory Comput. 5, 2322 (2009).","journal-title":"J. Chem. Theory Comput."},{"key":"47587_CR65","doi-asserted-by":"publisher","first-page":"7182","DOI":"10.1063\/1.328693","volume":"52","author":"M Parrinello","year":"1981","unstructured":"Parrinello, M. & Rahman, A. Polymorphic transitions in single crystals: a new molecular dynamics method. J. Appl. Phys. 52, 7182\u20137190 (1981).","journal-title":"J. Appl. Phys."},{"key":"47587_CR66","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/00268978300102851","volume":"50","author":"S Nos\u00e9","year":"1983","unstructured":"Nos\u00e9, S. & Klein, M. L. Constant pressure molecular dynamics for molecular systems. Mol. Phys. 50, 1055\u20131076 (1983).","journal-title":"Mol. Phys."},{"key":"47587_CR67","unstructured":"Schr\u00f6dinger, L. & DeLano, W. PyMOL. http:\/\/www.pymol.org\/pymol (2020)."},{"key":"47587_CR68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey, W., Dalke, A. & Schulten, K. VMD \u2013 visual molecular dynamics. J. Mol. Graph. 14, 33\u201338 (1996).","journal-title":"J. Mol. Graph."},{"key":"47587_CR69","doi-asserted-by":"publisher","first-page":"107322","DOI":"10.1016\/j.compbiolchem.2020.107322","volume":"87","author":"LP Kagami","year":"2020","unstructured":"Kagami, L. P., das Neves, G. M., Timmers, L. F. S. M., Caceres, R. A. & Eifler-Lima, V. L. Geo-Measures: A PyMOL plugin for protein structure ensembles analysis. Comput. Biol. Chem. 87, 107322 (2020).","journal-title":"Comput. Biol. Chem."},{"key":"47587_CR70","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.bpj.2015.08.015","volume":"109","author":"RT McGibbon","year":"2015","unstructured":"McGibbon, R. T. et al. MDTraj: a modern open library for the analysis of molecular dynamics trajectories. Biophys. J. 109, 1528\u20131532 (2015).","journal-title":"Biophys. J."},{"key":"47587_CR71","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"RA Laskowski","year":"2011","unstructured":"Laskowski, R. A. & Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778\u20132786 (2011).","journal-title":"J. Chem. Inf. Model."},{"key":"47587_CR72","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1093\/bioinformatics\/bty816","volume":"35","author":"A Vangone","year":"2019","unstructured":"Vangone, A. et al. Large-scale prediction of binding affinity in protein-small ligand complexes: the PRODIGY-LIG web server. Bioinformatics 35, 1585\u20131587 (2019).","journal-title":"Bioinformatics"},{"key":"47587_CR73","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1093\/bioinformatics\/btw514","volume":"32","author":"LC Xue","year":"2016","unstructured":"Xue, L. C., Rodrigues, J. P., Kastritis, P. L., Bonvin, A. M. & Vangone, A. PRODIGY: a web server for predicting the binding affinity of protein-protein complexes. Bioinformatics 32, 3676\u20133678 (2016).","journal-title":"Bioinformatics"},{"key":"47587_CR74","doi-asserted-by":"publisher","first-page":"W296","DOI":"10.1093\/nar\/gky427","volume":"46","author":"A Waterhouse","year":"2018","unstructured":"Waterhouse, A. et al. SWISS-MODEL: homology modeling of protein structures and complexes. Nucleic Acids Res. 46, W296\u2013W303 (2018).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47587-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47587-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47587-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T18:04:29Z","timestamp":1717783469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47587-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["47587"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-47587-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"30 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AH receives research funding from Cytokinetics and consults for Kainomyx. All other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4885"}}